27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Allergan plc (NYSE:AGN) has concluded its strategic review and now plans to sell its women’s health and infectious disease businesses, according to CNBC.
What Happened
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Allergan will redirect its focus to medical aesthetics and dermatology, ophthalmology, central nervous system and gastroenterology.
Shares initially fell 3 percent on the news but largely recovered by the time of publication Wednesday.
Why It’s Important
Cowen recently valued Allergan’s women’s health segment at around $4 billion and infectious diseases at $2 billion. Their sale would leave behind a growing set of assets Barclays considers central to the bull thesis.
What’s Next
CNBC’s David Faber suggested prospective buyers may opt to wait on the women’s health business until an August target date for a candidate that's under regulatory review.
Faber additionally predicted the sale proceeds would support buybacks and debt reduction.
Related Links:
Cantor Fitzgerald: 18 Drug Companies With Catalysts Worth Watching
CNBC: Allergan-Shire Deal Is DOA
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.